Who’s Going to ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
272 cancer centres, universities and companies, with 366 speakers and poster presenters and 16 exhibitors, at the EORTC-NCI-AACR (ENA) 2026 Symposium, a ~1,500-person, mostly biopharma meeting of preclinical and translational cancer scientists, phase I investigators and chemists. As of Nov 12, 2026.
| Organization | ENA 2026 Attendance |
|---|---|
MD Anderson Cancer Center Houston, Texas | |
University of Texas cancer centre for patient care, research and early-phase clinical trials. | Session Wed Nov 18 4:15–5:45pm Talk Wed Nov 18 4:55–5:15pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Talk Thu Nov 19 10–10:08am Talk Thu Nov 19 10:48–10:56am Talk Thu Nov 19 1:50–2:05pm Session Thu Nov 19 2–2:30pm Session Thu Nov 19 3–4:30pm Session Thu Nov 19 3–4:30pm Talk Thu Nov 19 3:20–3:40pm Talk Thu Nov 19 3:40–4pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Talk Fri Nov 20 12:48–12:56pm Talk Fri Nov 20 3–3:08pm Talk Fri Nov 20 4–4:08pm Talk Fri Nov 20 4:12–4:20pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain | |
Barcelona cancer research institute at Vall d'Hebron University Hospital, combining translational research with an early-phase clinical trials unit. | Session Wed Nov 18 1:30–1:35pm Talk Wed Nov 18 1:30–1:35pm Session Wed Nov 18 1:35–2:20pm Session Wed Nov 18 2:20–3:50pm Talk Thu Nov 19 3:20–3:40pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Session Fri Nov 20 8–9:30am Talk Fri Nov 20 8:40–9am Talk Fri Nov 20 9:45–10am Talk Fri Nov 20 12–12:08pm Session Fri Nov 20 3–4:50pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Memorial Sloan Kettering Cancer Center New York, NY | |
Cancer treatment and research centre with clinical, laboratory and computational research programmes. | Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Talk Thu Nov 19 8–8:20am Talk Thu Nov 19 11:12–11:20am Talk Thu Nov 19 4–4:20pm Session Thu Nov 19 5–6:30pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Talk Fri Nov 20 12:12–12:20pm Talk Fri Nov 20 1–1:08pm |
Find buyers from organizations at ENA 2026
Tell us what you sell and we’ll find the people at these organizations most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
When and where is ENA 2026?
38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics runs November 18–20, 2026, at CCIB in Barcelona, Spain.
What are the ENA 2026 exhibit hall hours?
The exhibit hall is open Wed, Nov 18, 12–7pm; Thu, Nov 19, 9am–5:30pm; Fri, Nov 20, 9am–3pm.
Where is the ENA 2026 program?
This guide lists every organization on the ENA 2026 program with its sessions; the full program is on the official website.
How do I register for ENA 2026?
Fees and registration are on the organizer's registration page.
What conference is this?
ENA 2026 is the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held November 18–20, 2026 in Barcelona and run jointly by the European Organisation for Research and Treatment of Cancer (EORTC), the US National Cancer Institute (NCI) and the American Association for Cancer Research (AACR). It brings together the scientists who discover and develop new cancer drugs, from targets and medicinal chemistry to preclinical models and phase I trials.
What is in this guide?
Every organization we can place at ENA 2026: the institutions of its 366 speakers, session chairs and poster presenters (423 talks, sessions and posters in the searchable programme) and the 16 exhibitors on the floor plan — 272 organizations in one list. People appear as a count, never by name, and abstracts are not shown.
How are organizations typed?
By the role an organization plays in cancer drug development: drug developers (large pharma and biotech), CROs, tools and service companies, cancer centres and hospitals, universities and institutes, and agencies, cooperative groups and societies. A poster’s topic is the poster category the organizers filed it under; a talk’s is its session’s theme.
How current is it?
Pulled from EORTC’s searchable programme and the exhibition floor plan on November 12, 2026, including the 31 late-breaking talks and posters listed by then. The organizers’ abstract release date is November 4, apart from media, embargoed or non-consented abstracts. This guide lists who presents what and never shows abstract text, so that date changes no row here.
Browse ENA 2026 by
- Molecular targeted agents, combinations and drug resistance 106
- Antibody–drug conjugates and radiopharmaceuticals 45
- Immunotherapy, immune engagers and the tumour microenvironment 35
- Cell therapies (CAR-T, TCR) 6
- Drug design and delivery, degraders and new agents 52
- Cancer genomics, molecular profiling and precision oncology 28
- Biomarker assays and translational studies 27
- Preclinical and animal models and drug screening 25
- Early clinical development, trial design and toxicity 27
- Artificial intelligence in cancer drug development 7
Organizations with their own page
87 organizations — every exhibitor and every organization with 2 or more presentations.
- Acrivon Therapeutics
- American Association for Cancer Research (AACR)
- Amgen
- Arcus Biosciences
- Arvinas
- Astellas
- Avammune
- Avistone Biotechnology
- Bantam Pharmaceutical
- Biocytogen
- BioNTech
- Blueprint Medicines
- BostonGene
- Bristol Myers Squibb
- Calico Life Sciences
- Cancer Research UK Manchester Institute
- Celltrion Pharm
- Centre de Recherche des Cordeliers
- Champions Oncology
- Chia Tai Tianqing
- Children's Cancer Institute
- Concr
- Crown Bioscience
- Dana-Farber Cancer Institute
- Earendil Labs
- Edison Oncology
- Eli Lilly
- European Organisation for Research and Treatment of Cancer (EORTC)
- Evotec
- Florida Cancer Specialists & Research Institute
- Foundation Medicine
- FUJIFILM Wako Pure Chemical
- Gustave Roussy
- Hanmi Pharmaceutical
- Iambic Therapeutics
- ICE Bioscience
- Immuneering
- Institut Curie
- Institute of Oncology Research (IOR)
- IRBM
- IRCCS Istituto Giannina Gaslini
- Istituto Nazionale dei Tumori, Milan
- John Paul II Catholic University of Lublin
- Kyinno
- Mallinckrodt Institute of Radiology
- Masaryk University
- Massachusetts General Hospital
- MD Anderson Cancer Center
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
- National Taiwan University
- Nerviano Medical Sciences
- Netherlands Cancer Institute
- NEXT Oncology
- Northern Centre for Cancer Care
- Novartis
- Nutshell Therapeutics
- OncoBone
- Oncolines
- OTR Therapeutics
- Pfizer
- Princess Margaret Cancer Centre
- Pyxis Oncology
- Reaction Biology
- Revolution Medicines
- Ryvu Therapeutics
- Shanghai Hongcheng Biopharma
- START Center for Cancer Research
- Studylog Systems
- The Catholic University of Korea
- The Institute of Cancer Research
- Toyo University
- Turbine
- UCLA Health
- University of California, San Francisco
- University of Edinburgh
- University of Helsinki
- University of Michigan
- University of Porto
- University of Turin
- Urosphere
- Vall d'Hebron Institute of Oncology (VHIO)
- Wellcome Sanger Institute
- WuXi AppTec
- XenTech
- Yale University
- Zymeworks
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction